COYA
Coya Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.20
−1.18%Year over year
Reported trailing growth
- Revenue
- +1793.8%
- EBITDA
- -0.8%
- EBIT
- -0.1%
- EPS
- +13.7%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -45.8%
- EBITDA
- -54.3%
- EPS
- -35.7%
Three-year CAGR
- Revenue
- +15.1%
- EBITDA
- -23.2%
- EBIT
- -17.5%
- Net income
- -42.6%
- EPS
- -29.6%
- Free cash flow
- -4.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026